Insights
Summarizing Pharma-Biotech Deals 2025
4 Surprising Trends Shaping the Future of Biopharma Deals
Massive biopharma deals are more than just big numbers; they are a roadmap for the future of innovation. We’re looking past the headlines to analyze the strategic trends and technologies driving today’s biggest investments. If you’re a numbers person, feel free to skip to the data-backed insights at the end.
1. Pharma 🤝 AI
For years, “AI in drug discovery” felt like one of those buzzwords everyone uses and a must attend session at conferences. Recent deal data confirms it is no longer an experiment, but a multibillion-dollar core strategy. These partnerships demonstrate the trust and belief that AI can decode biology and design novel drugs faster than ever before.
However, the headlines rarely explain the “why” behind the buy. Are companies paying for a sophisticated technology platform, or for the promising drug assets the AI has already generated? To understand what pharma is actually buying, let’s look at the landmark deals defining this shift:
Takeda & Nabla Bio: AI-based de novo antibodies for multiple targets with a potential value of up to more than $1 billion.
Why Them?
a. At the core of the partnership is Nabla Bio’s proprietary Joint Atomic Model (JAM), which is positioned as a foundation-style biomolecular design model that can iterate rapidly from design + testing cycles in ~3–4 weeks. This rapid iteration provides the exact speed Takeda needs to accelerate its discovery of complex antibodies and multispecifics.
b. The collaboration directly supports Takeda’s recent R&D realignment. As the company exits cell therapy and narrows its focus, it is using AI-driven design to fill early-stage gaps and tackle hard-to-target biologics.
c. This second collaboration builds on the success of the first program, making it a natural choice over competitors.
What are they Buying?
This is primarily platform-driven deal, not a purchase of an existing drug candidate. Takeda will apply JAM across its own early-stage programs, designing antibodies, multispecifics, and other complex protein therapeutics. Upfront payment undisclosed.
Merck KGaA & Valo Health: A licensing collaboration worth up to $3 billion centered on Valo’s AI discovery platform to identify new neurology treatments.
Why Them?
a. Valo’s core strength is its human causal biology platform, which integrates AI with massive longitudinal human patient data (over 17 million de-identified records plus biobank samples) to uncover disease mechanisms, patient subtypes, and therapeutic targets grounded in real human biology, and by that to reduce late-stage failure due to poor translational fidelity.
b. Valo’s platform generates and optimize small molecules designed to engage those targets, which gives an edge over tools focused only on target scoring or virtual screening.
c. Merck is seeking new mechanistic insights and programs, so using real-world phenotypes and mechanistic signatures rooted in human data may reduce attrition risk downstream
What are they Buying?
Valo does have internal programs, but this Merck KGaA deal is primarily centered on Valo’s AI-enabled human causal biology platform, applied to Parkinson’s disease and related neurological disorders, rather than licensing a specific pre-existing Valo asset. Upfront payment undisclosed.
Roche & Manifold Bio: A licensing deal valued at up to $2 billion for an AI-enabled protein engineering platform designed to optimize multiple brain-targeted therapeutic modalities.
Why Them?
a. Manifold’s differentiator isn’t “AI for target discovery”, it’s AI-guided direct-to-vivo discovery paired with a tissue-targeting shuttle portfolio. Measure thousands to millions of biologic variants directly in vivo, providing physiologically relevant data at unprecedented scale and provide experimental grounding.
b. Roche has invested for years in strategies to cross the BBB, but BBB delivery is still a major bottleneck for CNS biologics and complex modalities. Roche frames Manifold as a partner to identify the “next generation” of highly specific shuttles.
What are they Buying?
Roche isn’t just getting a model; it’s getting access to a tissue-targeting shuttle portfolio plus Manifold’s mDesign direct-to-vivo discovery engine to generate BBB shuttles across modalities tailored to Roche therapeutic payloads, with Roche taking them forward. Manifold to receive $55 million upfront, with potential for over $2 billion in total research, preclinical, clinical development and commercial milestones.
Novartis & Relation Therapeutics: A licensing partnership for up to $1.7 billion to apply Relation’s “Lab-in-the-Loop” AI platform to discover new therapies for inflammatory diseases.
Why Them?
a. Relation’s Lab-in-the-Loop platform is designed to combine AI with multi-omic human data and functional studies directly from patient tissue, connecting causal disease mechanisms with human biology, setting them apart from many purely computational AI companies that may lack strong experimental integration.
b. This gives Novartis a data-rich foundation for target validation before advancing into drug development to reduce late-stage failure rates.
c. Novartis has been expanding its footprint in immune-related diseases and dermatology with recent successes and pipeline assets, and this collaboration fits that therapeutic strategy.
What are they Buying?
The primary value is in the platform and discovery engine, not in pre-built drug assets. Novartis gains exclusive rights to targets and programs that emerge from this collaboration and will take the assets forward into clinical development. Relation will receive $55 million, comprising an upfront payment, equity investment and additional R&D funding.
2. Mega-Deals, Mega-Markets
The intense investment focused on endocrinology and metabolic disorders, especially obesity, has reached a fever pitch. This field is fueled by projections of a $100 billion-plus global market for obesity therapies within the decade. Pharma giants are acquiring decades of revenue from a condition affecting hundreds of millions of patients worldwide, along with its costly comorbidities like MASH (Metabolic dysfunction-associated steatohepatitis) and cardiovascular disease.
This goes far beyond simple licensing deals. We are seeing multi-billion-dollar acquisitions of entire companies just to secure a single promising asset or platform. The race is on to develop treatments that are more effective, have better safety profiles, or offer more convenient dosing, redefining what it means to be a “blockbuster” drug in the modern era. This field is exciting and full with innovation, and just last week Novo Nordisk announced that the US FDA has approved the once-daily oral administration of Wegovy pill, a major step offering easier access than injections. Recent deals:
Pfizer & Metsera: A major acquisition of Metsera’s GLP-1 agonist pipeline in a deal valued at up to $7 billion.
Behind the headline- Pfizer–Metsera acquisition is fundamentally about acquiring assets and technological capability within a therapeutic area. Metsera brought Pfizer a suite of promising clinical-stage candidates, like MET-097i (a weekly and monthly injectable GLP-1 receptor agonist expected to enter Phase 3), MET-233i (a monthly amylin analog) and an Oral GLP-1 candidates poised to move into clinical testing. The acquisition accelerates Pfizer’s entry into obesity and cardiometabolic diseases without having to build similar clinical pipelines from scratch, providing Pfizer with long-term growth drivers and competitive relevance.
Novo Nordisk & Akero Therapeutics: An acquisition of Akero for up to $5.2 billion to gain its late-stage asset, efruxifermin.
Behind the headline – Efruxifermin (EFX) is a Phase 3 treatment candidate for MASH, a serious liver disease closely linked to obesity, diabetes, and metabolic disorders, core therapeutic areas for Novo Nordisk, which allows them to expand beyond the existing obesity and diabetes blockbusters amid rising competition (e.g., from Eli Lilly). The deal was valued at approximately $4.7 billion in cash plus an additional potential $0.5 billion contingent value right (CVR).
Pfizer & YaoPharma: A licensing deal valued at up to $2 billion for GLP-1 agonist assets.
Behind the headline – An exclusive global collaboration and license agreement with YaoPharma for the development, manufacture, and commercialization of YP05002, a small-molecule GLP-1 receptor agonist currently in Phase I clinical development for chronic weight management. YaoPharma receives $150 million upfront, plus up to ~$1.9 billion in milestones and royalties if the asset is approved. This deal is part of Pfizer’s broader push to build out its cardiometabolic and obesity pipeline, coming just after its acquisition of Metsera.
Roche & 89bio: An acquisition worth up to $3.5 billion for 89bio’s protein therapeutic, pegozafermin, promising asset for treating MASH.
Behind the headline – Roche’s acquisition is primarily about securing pegozafermin, which has shown promise as a potential best-in-class FGF21 analogue addressing both anti-fibrotic and anti-inflammatory mechanisms in MASH. Roche has been actively strengthening its metabolic and liver disease portfolio through deals (e.g., Zealand Pharma, Carmot Therapeutics), indicating a strategic push into this therapeutic domain.
3. Attractivity of Innovative Platforms
There’s a quite shift happening in recent M&As: the biggest players aren’t just buying individual drugs, they’re buying entire technology platforms and paying fortunes to own the foundational tools and tech that can create multiple future therapies.
The thinking here is straightforward: why buy one product when you can own the innovation engine itself? By acquiring a platform, whether it’s for RNA therapeutics, gene editing, or novel drug conjugates, a company locks in a sustainable pipeline for years down the line. Some of these acquisitions are huge and grab headlines, but even the smaller ones show that owning a unique technological engine can be just as valuable as landing a single blockbuster drug:
Novartis & Avidity Biosciences: A $12 billion acquisition to gain control of Avidity’s entire Antibody-Oligonucleotide Conjugate (AOC) platform.
Behind the Headline – The acquisition brings both clinical assets and a differentiated RNA delivery platform to Novartis, using Avidity’s AOC platform, a technology that combines antibody specificity with nucleic acid precision to deliver RNA therapeutics directly into muscle tissue. Novartis will integrate Avidity’s late-stage programs into its pipeline (del-zota for DMD, del-desiran for DM1 and del-brax for FSHD). Avidity’s early-stage precision cardiology programs will be spun off into a separate company before closing. Beyond just acquiring assets, this deal is about owning a high-value platform that reaches previously “undruggable” targets, representing strategic growth.
BMS & Orbital Therapeutics: A $1.5 billion deal to acquire Orbital’s RNA platform and its lead CAR-T asset.
Behind the Headline – Orbital’s core value lies in its in vivo approach to CAR-T, which could dramatically reduce the complexity, cost, and logistical burden associated with classical CAR-T cell therapies. From BMS’s perspective, the acquisition is essentially a combination of capabilities and candidates as it includes the both the asset OTX-201, representing a new class of in vivo CAR-T immunotherapy, and Orbital’s proprietary RNA technology platform, built to integrate circular and linear RNA engineering, LNP delivery, and AI-guided design for programmable RNA drugs across disease areas.
Regeneron & Tessera Therapeutics: A $275 million deal for “Gene-writing platform” for rare diseases including Alpha-1 Antitrypsin Deficiency (AATD).
Behind the Headline – Global collaboration to jointly develop and commercialize TSRA-196, an in vivo gene-editing therapy designed as a one-time gene-writing treatment to precisely correct the underlying SERPINA1 genetic mutation and restore production of functional alpha-1 antitrypsin protein, to treat a rare inherited liver and lung disease. Regeneron is paying $150 million upfront (cash + equity) and Tessera stands to receive up to an additional $125 million in development milestones. For Regeneron this offers a way to expand its capabilities beyond typical gene therapy/CRISPR models.
4. The Rise of Chinese Biotech
The global map of biopharma innovation is clearly shifting. Once a net importer of biotech, China is now a global powerhouse, with Western giants spending assumingly $66B in 2025 to license Chinese-developed therapies.
Driven by government backing and a deep pool of Western-trained talent, China has become the frontier for AI drug design and Antibody-Drug Conjugates (ADCs) responsible for roughly 70% of global development in next-gen cancer therapies. Western players are no longer just competing with China, they’re racing to partner with it.
A partnership valued at up to $5.33 billion for an AI-enabled drug discovery platform, which uses AI to design novel small-molecule therapies. The research will be carried out in China, and AstraZeneca gains options to globally license any promising candidates, reflecting its confidence in Chinese R&D capabilities
A licensing deal for an ADC pipeline from Hansoh Pharma, with a potential value of up to $1.45 billion. Hansoh’s experimental ADC targets a molecule linked to colorectal and other solid tumors and showed early promise in trials. with an upfront of $80 million, Roche obtained exclusive worldwide rights to develop and commercialize the drug, excluding China, signaling a shift where Chinese innovators negotiate from a position of strength.
Even smaller Western players are tapping Chinese innovation with $80 million upfront payment. A licensing deal for oncology biologics worth up to $1.33 billion. Crescent gained global rights outside of China on a SKB105, an integrin-targeting ADC being set for trials against solid tumors.
A Glimpse into the Future
The patterns underlying recent biopharma deals paint a clear picture of the industry’s future. The integration of AI is no longer optional, the race for metabolic disease dominance is on, complex platforms are growing interest, and the geography of innovation has expanded, with China emerging as a key player. These four trends are not isolated events but interconnected forces driving the next wave of breakthroughs.
Statistics
Diving into the numbers to support the points above, 260 deals were identified this year, with a total disclosed value of nearly $280B (with 26% of deals having undisclosed financial terms). Eli Lilly leads by number of deals, with 24 transactions, nearly double those of Sanofi (13) and Novartis (12).
Looking at technologies, small molecules continue to dominate, as in previous years, accounting for ~20% of deals. Biologics follow, including monoclonal antibodies (10.4%) and bispecific antibodies (8.4%). In line with the trends discussed above, ADCs represent a notable 6.8% of deals.
From a therapeutic area perspective, oncology remains the leading category at 30%, followed by immunology and autoimmune diseases at 15%. Surprisingly, both the number of deals and total investment in metabolic disorders continue to rise year over year, reaching potentially $39.5B across 28 deals.
Geographically, the U.S. leads both as the top payer ($120B) and top recipient ($155B), underscoring its central role in innovation. However, a notable shift is emerging, with China becoming the second-largest recipient, attracting $65B in deal value.
Focusing specifically on AI-driven deals, which account for 12% of all deals this year, Eli Lilly again leads with six transactions, followed by AstraZeneca (three) and Sanofi (two). Based on disclosed figures, $30B has been invested in AI-related deals (upfront+ milestones). Beyond small molecules and biologics, 20% of these AI deals focus on target identification, rather than direct asset co-development. As expected, when examining therapeutic areas within AI deals, oncology and immunology/autoimmune diseases, or combination of both, are leading.
